Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E. O'Dwyer, Ronan Swords, Arnon Nagler, Mary Frances McMullin, Philipp D. le Coutre, Stephen E. Langabeer, Alberto Alvarez-Iglesias, Hongxin Fan, Richard C. Woodman, Francis J. Giles, Eibhlin Conneally

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response'. Together they form a unique fingerprint.

Medicine & Life Sciences